James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 10,896 shares at $3.47 ($38K) on 2025-03-31, disclosed to the SEC on 2025-04-02.
Open-market sale of $38k AMLX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |